Jump to navigation Jump to search


WikiDoc Resources for Daclizumab


Most recent articles on Daclizumab

Most cited articles on Daclizumab

Review articles on Daclizumab

Articles on Daclizumab in N Eng J Med, Lancet, BMJ


Powerpoint slides on Daclizumab

Images of Daclizumab

Photos of Daclizumab

Podcasts & MP3s on Daclizumab

Videos on Daclizumab

Evidence Based Medicine

Cochrane Collaboration on Daclizumab

Bandolier on Daclizumab

TRIP on Daclizumab

Clinical Trials

Ongoing Trials on Daclizumab at Clinical Trials.gov

Trial results on Daclizumab

Clinical Trials on Daclizumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Daclizumab

NICE Guidance on Daclizumab


FDA on Daclizumab

CDC on Daclizumab


Books on Daclizumab


Daclizumab in the news

Be alerted to news on Daclizumab

News trends on Daclizumab


Blogs on Daclizumab


Definitions of Daclizumab

Patient Resources / Community

Patient resources on Daclizumab

Discussion groups on Daclizumab

Patient Handouts on Daclizumab

Directions to Hospitals Treating Daclizumab

Risk calculators and risk factors for Daclizumab

Healthcare Provider Resources

Symptoms of Daclizumab

Causes & Risk Factors for Daclizumab

Diagnostic studies for Daclizumab

Treatment of Daclizumab

Continuing Medical Education (CME)

CME Programs on Daclizumab


Daclizumab en Espanol

Daclizumab en Francais


Daclizumab in the Marketplace

Patents on Daclizumab

Experimental / Informatics

List of terms related to Daclizumab

Daclizumab (Zenapax) is a humanized monoclonal antibody to the IL-2Rα receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

It is given in multiple doses, the first 1 hour before the transplant operation and 5 further doses given at two week intervals after the transplant. These saturate the receptors and prevent T cell activation and thus prevent formation of antibodies against the transplant.

Like the similar drug basiliximab, daclizumab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections.

Daclizumab can also be used in place of a calcineurin-inhibitor (ciclosporin or tacrolimus) in the early phase after kidney transplantation when the kidney is recovering and vulnerable to calcineurin-inhibitor toxicity. This has been shown to be beneficial in non-heart beating donor kidney transplantation.

In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.

Daclizumab is now being tested as a possible Multiple Sclerosis treatment in a phase 2 clinical trial across the United States and Europe, which started 2006 and will end in 2007. It has also been used to arrest the progression of autoimmune diseases, especially birdshot retinochoroidopathy.

External links

Template:Immunosuppressants Template:Humanizedmonoclonals


Template:Jb1 Template:WH Template:WikiDoc Sources